TirzepatideRanked
Find my match
Price index re-read 2026-10-15 NexLife prices 2026-11-06 Methodology v4.1 Programs priced 28 Corrections open log

Trial review

Tirzepatide and Type 2 Diabetes Prevention

Progression to type 2 diabetes

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Direct answer

SURMOUNT-1, three-year prediabetes analysis was a prespecified analysis of a phase 3 randomised double-blind placebo-controlled trial funded by Eli Lilly and Company. Three years of tirzepatide produced substantial sustained weight reduction and a markedly lower risk of progression to type 2 diabetes than placebo. That figure belongs to the population, dose, comparator and 176 weeks of treatment followed by a 17-week off-treatment period shown below, and describes a group average under trial conditions rather than a prediction for any individual.

Answer last reviewed: Evidence:
SURMOUNT-1, three-year prediabetes analysis at a glanceVerified
Data table
DesignPrespecified analysis of a phase 3 randomised double-blind placebo-controlled trial
PopulationThe 1,032 SURMOUNT-1 participants who had both obesity and prediabetes
Sample size1,032 of 2,539
InterventionTirzepatide once weekly
ComparatorPlacebo
Duration176 weeks of treatment followed by a 17-week off-treatment period
Primary endpointProgression to type 2 diabetes, plus three-year weight change and safety
Main resultThree years of tirzepatide produced substantial sustained weight reduction and a markedly lower risk of progression to type 2 diabetes than placebo
NCT NCT04184622 · DOI 10.1056/NEJMoa2410819Last source check: 2026-07-24
How to read SURMOUNT-1, three-year prediabetes analysis without over-reading it
1Who was eligibleThe 1,032 SURMOUNT-1 participants who had both obesity and prediabetes2What they receivedTirzepatide once weekly3What it was compared againstPlacebo4For how long176 weeks of treatment followed by a 17-week off-treatment period5What was measured firstProgression to type 2 diabetes, plus three-year weight change and safety6What the group average wasThree years of tirzepatide produced substantial sustained weight reduction and a markedl7What it does not tell youA group average is not a prediction for any individual reader.
Show this figure as a table
Data table
StepStageWhat happens
1Who was eligibleThe 1,032 SURMOUNT-1 participants who had both obesity and prediabetes
2What they receivedTirzepatide once weekly
3What it was compared againstPlacebo
4For how long176 weeks of treatment followed by a 17-week off-treatment period
5What was measured firstProgression to type 2 diabetes, plus three-year weight change and safety
6What the group average wasThree years of tirzepatide produced substantial sustained weight reduction and a markedly lower risk of progression to type 2 diabetes than placebo
7What it does not tell youA group average is not a prediction for any individual reader.
Strip any step and the result stops meaning what the trial found.
Primary results, from the peer-reviewed publicationNew England Journal of Medicine, published 13 November 2024, updated 6 March 2025
Intervention groupnot capturedComparator groupnot captured
Show this figure as a table
Data table
ItemWeight changeEvidence
Intervention groupnot captured
Comparator groupnot captured
Bars fill only from the peer-reviewed publication. Topline and press-release figures are labelled as such and are never charted as results.
What this trial can and cannot tell you
What this trial can and cannot tell you
QuestionPosition
Average effect in the studied populationReported once captured
Your individual outcomeNot predicted by any trial
Effect of a compounded preparationNot studied here
Effect at doses outside the protocolNot studied here
Effect after stoppingOnly if the trial included a withdrawal phase
Long-term safety beyond the trialOutside the observation window

Who was studied

This analysis comes from SURMOUNT-1, which randomised 2,539 adults with a BMI of 30 or more, or 27 or more with a weight-related condition (high blood pressure, abnormal lipids, obstructive sleep apnea or cardiovascular disease), who did not have diabetes. All had at least one past diet attempt that had not worked.

The three-year analysis covers the 1,032 participants who had prediabetes when they were randomised: 762 assigned to tirzepatide and 270 to placebo. Only this group continued treatment past week 72. Sites were in Argentina, Brazil, China, India, Japan, Mexico, Russia, Taiwan, the United States and Puerto Rico.

Not studied: people who already had diabetes; anyone whose weight had changed by more than 5 kg in the previous three months; people with past pancreatitis or a personal or family history of medullary thyroid carcinoma or MEN-2; people with significant depression or another severe psychiatric disorder in the previous two years, or any past suicide attempt; people with prediabetes but without obesity or overweight; and anyone under 18.

Sources: ClinicalTrials.gov (NCT04184622) and Jastreboff et al., NEJM 2025;392:958-971 (abstract via PubMed, PMID 39536238), read November 9, 2026.

What was given, and what it was compared against

  • Tirzepatide at a fixed dose of 5 mg, 10 mg or 15 mg once a week, assigned at random. Everyone started at 2.5 mg and stepped up by 2.5 mg every four weeks until reaching their assigned dose.
  • The comparator was placebo, in matching weekly injections. The trial was double-blind, with randomisation 1:1:1:1 across the four groups.
  • Timing. Treatment ran for 176 weeks, about three years and four months. A 17-week period off treatment followed, ending at week 193, to see what happened after stopping.

The diabetes results pool the three tirzepatide doses and compare them with placebo. The weight results are reported dose by dose.

The three-year endpoints were key secondary endpoints of SURMOUNT-1, with control for false-positive results (type I error). The trial's primary endpoints were weight change at 72 weeks, reported earlier.

Results

Weight at 176 weeks (NEJM abstract): −12.3% on 5 mg, −18.7% on 10 mg and −19.7% on 15 mg, against −1.3% on placebo (P<0.001 for each). The abstract does not name the estimand.

Type 2 diabetes diagnosed during 176 weeks of treatment: 1.3% on tirzepatide against 13.3% on placebo, hazard ratio 0.07 (95% CI 0.0 to 0.1), P<0.001. In absolute terms, about 1 in 77 people on tirzepatide against about 1 in 8 on placebo.

After 17 weeks off treatment (week 193): 2.4% against 13.7%, hazard ratio 0.12 (95% CI 0.1 to 0.2), P<0.001.

On-treatment figures. The ClinicalTrials.gov results record also gives weight changes that exclude data after people stopped treatment early: −15.4%, −19.9% and −22.9% on 5, 10 and 15 mg, against −2.1% on placebo. On the same basis, 90.6%, 91.9% and 94.8% lost at least 5% of their weight, against 24.6% on placebo. These answer a different question from the abstract figures: what happens if you stay on treatment.

Adverse events and discontinuations

The NEJM abstract says that, apart from COVID-19, the most common adverse events were gastrointestinal. Most were mild to moderate and happened mainly during the first 20 weeks, while the dose was going up. It reports no new safety signals.

The ClinicalTrials.gov results record reports safety for all 2,539 SURMOUNT-1 participants through week 193, not only the prediabetes group:

EventPlacebo (643)5 mg (630)10 mg (636)15 mg (630)
Serious adverse events8.2%9.0%9.4%7.9%
Nausea9.8%25.4%34.1%31.9%
Deaths4432

Discontinuation. Over the first 72 weeks, side effects led to stopping treatment in 4.3%, 7.1% and 6.2% on 5, 10 and 15 mg, against 2.6% on placebo (SURMOUNT-1 72-week paper, abstract). The abstract for the three-year analysis gives no discontinuation rate. Of the prediabetes participants who started weeks 72 to 176, 182 of 213 on placebo and 629 of 688 on tirzepatide completed that period.

Limitations

  • Funding. Eli Lilly funded the trial, and several authors are Lilly employees.
  • Prevention or delay? Tirzepatide lowers blood sugar directly, so some of the gap during treatment may reflect diabetes being held back rather than prevented. The 17-week off-treatment period tests this only partly. Diagnoses on tirzepatide rose from 1.3% to 2.4% after stopping, and 17 weeks is short.
  • Few events. Diagnoses on tirzepatide were rare, so the hazard ratio is imprecise, even though its interval sits well below 1.
  • Dropout. More people left the placebo group. In the first 72 weeks, 134 of 643 placebo participants did not finish, against 55 to 70 per tirzepatide group. Uneven dropout makes missing-data handling matter.
  • Pooled doses. The diabetes result combines 5, 10 and 15 mg, so it cannot say which dose is needed.
  • Population. Everyone had obesity or overweight with a complication, and many groups were excluded. Results may not apply to people with prediabetes at a lower weight.

How this should and should not be read

A fair reading: in adults with obesity and prediabetes, about three years of tirzepatide led to far fewer diagnoses of type 2 diabetes than placebo. The gap was still large 17 weeks after treatment stopped.

Common misreadings:

  • "Tirzepatide cures prediabetes." The trial counted new diabetes diagnoses. It did not test a permanent return to normal blood sugar.
  • "Three years and you can stop." After stopping, diagnoses on tirzepatide nearly doubled within 17 weeks, from 1.3% to 2.4%. Longer-term effects off treatment are unknown.
  • "My diabetes risk falls 93%." The hazard ratio of 0.07 is a group-level relative figure. The absolute difference was 1.3% against 13.3% over 176 weeks.
  • "It works without obesity." Only people with obesity, or overweight with a complication, were studied.
  • "Compounded tirzepatide does the same." Only the manufacturer's product was tested.

This trial does not make diabetes prevention a labelled use. Check the current prescribing information with your clinician.

How it compares with other trials

  • SURMOUNT-1 at 72 weeks was the same trial in a broader group, people with and without prediabetes. It reported −20.9% at 15 mg against −3.1% on placebo (treatment-regimen estimand). The 176-week figure of −19.7% at 15 mg in the prediabetes group suggests weight loss was largely held while treatment continued. The population and time point differ, so treat this as a consistency check.
  • SURMOUNT-4 tested what happens to weight when tirzepatide is swapped for placebo. Its finding of regain fits the rise in diabetes diagnoses after stopping here, though the endpoints differ.
  • Lifestyle and metformin trials, such as the Diabetes Prevention Program, were run in a different era, with different interventions, populations and definitions of diabetes. Their figures cannot be lined up with these.
  • Trials in people who already have type 2 diabetes (the SURPASS program; see tirzepatide in type 2 diabetes) answer a treatment question, not a prevention question.

Questions readers actually ask

Does this mean I would lose that much weight?

No. Trials report group averages under controlled conditions with specific eligibility criteria. Individual results vary widely, and the trial population may not resemble you.

Do these results apply to compounded tirzepatide?

Not automatically. Trials studied the approved product at studied doses. A compounded preparation at a different concentration, formulation or route has not been through those trials.

Cite this pageCC BY 4.0

Tirzepatide Ranked. “Tirzepatide and Type 2 Diabetes Prevention.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/research/tirzepatide-diabetes-prevention/

Quote the capture date beside a figure, not the date you read this page. Why.

Report an error
Comparing 0 of 4